Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
作者： Li Li , Bei-Bei Ni , Qing-Hua Zhong , Yan-Hui Liu , Ming-Hui Zhang
关键词: KRAS 、 Correlation 、 DNA mismatch repair 、 Internal medicine 、 Gene 、 Incidence (epidemiology) 、 Oncology 、 Neuroblastoma RAS viral oncogene homolog 、 Mutation 、 Medicine 、 Chemotherapy
摘要: Aim: To investigate the relationship between mutations of key genes in EGFR signaling pathway and prognosis stage II colorectal cancer patients without chemotherapy. Materials & methods: The incidence KRAS, NRAS, BRAF, PIK3CA deficient DNA mismatch repair were assessed 160 who had been treated by radical operation adjuvant Results: Mutations BRAF or associated with poor prognosis, while status was not prognosis. Combining these three markers, sensitivity predicted value for progression-free survival overall reached 0.645 (p = 0.002) 0.709 0.001), respectively. Conclusion: Knowing mutation can significantly improve accuracy prognoses.
sci-hub.se 参考文章(54)
Jian-ming Ying, Ning Lü, Lei Guo, Tian Qiu, Yun Ling, Ling Shan, [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. Chinese Journal of Pathology. ,vol. 41, pp. 590- 594 ,(2012) , 10.3760/CMA.J.ISSN.0529-5807.2012.09.004
Marta Schirripa, Chiara Cremolini, Fotios Loupakis, Manfredi Morvillo, Francesca Bergamo, Federica Zoratto, Lisa Salvatore, Carlotta Antoniotti, Federica Marmorino, Elisa Sensi, Cristiana Lupi, Gabriella Fontanini, Veronica De Gregorio, Riccardo Giannini, Fulvio Basolo, Gianluca Masi, Alfredo Falcone, Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer International Journal of Cancer. ,vol. 136, pp. 83- 90 ,(2015) , 10.1002/IJC.28955
Brigette B Ma, Frankie Mo, Joanna H Tong, Ashley Wong, SC Cesar Wong, Wing M Ho, Cherry Wu, Polly WY Lam, KF Chan, Timothy SK Chan, Wilson MS Tsui, Alex KH Tsang, Mandy NS Fung, Anthony TC Chan, Ka Fai To, None, Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. Asia-pacific Journal of Clinical Oncology. ,vol. 11, pp. 160- 169 ,(2015) , 10.1111/AJCO.12342
D. Forman, P. Quirke, E. J A Morris, N. J Maughan, Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology Gut. ,vol. 56, pp. 1419- 1425 ,(2007) , 10.1136/GUT.2006.116830
B Dieumegard, S Grandjouan, J-C Sabourin, M-L Le Bihan, I Lefrère, Bellefqih, J-P Pignon, P Rougier, P Lasser, J Bénard, D Couturier, B Bressac-de Paillerets, Extensive molecular screening for hereditary non-polyposis colorectal cancer. British Journal of Cancer. ,vol. 82, pp. 871- 880 ,(2000) , 10.1054/BJOC.1999.1014
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4
Dora Colussi, Giovanni Brandi, Franco Bazzoli, Luigi Ricciardiello, Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention International Journal of Molecular Sciences. ,vol. 14, pp. 16365- 16385 ,(2013) , 10.3390/IJMS140816365
Timothy J Price, Maressa A Bruhn, Chee K Lee, Jennifer E Hardingham, Amanda R Townsend, Kristy P Mann, John Simes, Andrew Weickhardt, Joseph W Wrin, Kate Wilson, Val Gebski, Guy Van Hazel, Bridget Robinson, David Cunningham, Niall C Tebbutt, Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer. ,vol. 112, pp. 963- 970 ,(2015) , 10.1038/BJC.2015.37
Kankana Bardhan, Kebin Liu, Epigenetics and Colorectal Cancer Pathogenesis Cancers. ,vol. 5, pp. 676- 713 ,(2013) , 10.3390/CANCERS5020676
D Tougeron, G Sickersen, G Mouillet, A Zaanan, I Trouilloud, R Coriat, T Aparicio, G Des Guetz, C Lecaille, P Artru, E Cauchin, D Sefrioui, T Boussaha, A Ferru, T Matysiak-Budnik, C Silvain, L Karayan-Tapon, JC Pagès, D Vernerey, F Bonnetain, P Michel, J Taïeb, T Lecomte, Association des Gastro-Entérologues Oncologues, None, Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study European Journal of Cancer. ,vol. 51, pp. 925- 934 ,(2015) , 10.1016/J.EJCA.2015.03.011